Study of biomaterial-induced macrophage activation, cell-mediated immune response and molecular oxidative damage in patients with dermal bioimplants

Immunobiology

Volumn 217, Issue 1, 2012, Pages 44-53

  Sánchez, Olga ^a,d   Rodríguez Sureda, Víctor ^a,b   Domínguez, Carmen ^a,b   Fernández Figueras, Teresa ^c   Vilches, Angel ^a   Llurba, Elisa ^a,b,d   Alijotas Reig, Jaume ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Bioimplants; Chitotriosidase; Dermal fillers; Innate immunity; Myeloperoxidase; Oxidative stress; YKL 40

Indexed keywords

ACRYLAMIDE DERIVATIVE; BIOMATERIAL; CHITINASE; CHITOTRIOSIDASE; FILLER; HYALURONIC ACID; HYDROXYAPATITE; LIPID; METHACRYLIC ACID; MYELOPEROXIDASE; PROTEIN; SILICONE; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CATALYSIS; CELLULAR IMMUNITY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSTIMULATION; IMPLANT; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; OXIDATIVE STRESS; PEROXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN BIOPSY;

ADIPOKINES; ADMINISTRATION, CUTANEOUS; ADULT; AGED; BIOCOMPATIBLE MATERIALS; BIOLOGICAL MARKERS; FEMALE; HEXOSAMINIDASES; HUMANS; HYALURONIC ACID; IMMUNITY, CELLULAR; LECTINS; LIPID PEROXIDATION; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIDASE; PROSTHESES AND IMPLANTS;

EID: 82155185170     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.08.003     Document Type: Article

References (48)

1. Alcalay J., Alcalay R., Gat A., Yorav S. Late-onset granulomatous reaction to Artecoll. Dermatol. Surg. 2003, 29:859-862.
2. Alijotas-Reig J., García-Giménez V. Delayed immune-mediated adverse effects related to hyaluronic acid and acryl hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature. J. Eur. Acad. Dermatol. Venereol. 2008, 22:150-161.
3. Alijotas-Reig J., Hindié M., Kandhaya-Pillai R., Miro-Mur F. Bioengineered hyaluronic acid elicited a nonantigenic T cell activation: implications from cosmetic medicine and surgery to nanomedicine. J. Biomed. Mater. Res. A 2010, 95:180-190.
4. Alijotas-Reig J., Miró-Mur F., Planells-Romeu I., Garcia-Aranda N., Garcia-Gimenez V., Vilardell-Tarrés M. Are bacterial growth and/or chemotaxis increased by filler injections? Implications for the pathogenesis and treatment of filler-related granulomas. Dermatology 2010, 221:356-364.
5. Andre P., Lowe N.J., Parc A., Clerici T.H., Zimmermann U. Adverse reactions to dermal fillers: a review of European experiences. J. Cosmet. Laser Ther. 2005, 7:171-176.
6. Bachmann F., Erdmann R., Hartmann V., Becker-Wegerich P., Wiest L., Rzany B. Adverse reactions caused by consecutive injections of different fillers in the same facial region: risk assessment based on the results from the Injectable Filler Safety study. J. Eur. Acad. Dermatol. Venereol. 2010, 10.1111/j.14683083.2010.03878.x.
7. Baskol G., Demir H., Baskol M., Kilic E., Ates F., Karakukcu C., Ustdal M. Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis. Cell Biochem. Funct. 2006, 24:307-311.
8. Boot R.G., Renkema G.H., Strijland A., van Zonneveld A.J., Aerts J.M. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J. Biol. Chem. 1995, 270:26252-26256.
9. Bussink A.P., van Eijk M., Renkema G.H., Aerts J.M., Boot R.G. The biology of the Gaucher cell: the cradle of human chitinases. Int. Rev. Cytol. 2006, 252:71-128.
10. Chang L.T., Chua S., Sheu J.J., Wu C.J., Yeh K.H., Yang C.H., Yip H.K. Level and prognostic value of serum myeloperoxidase in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ. J. 2009, 73:726-731.
11. Chen G.Y., Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 2010, 10:826-837.
12. Clark C.P. Animal-based hyaluronic acid fillers: scientific and technical considerations. Plast. Reconstr. Surg. 2007, 120(Suppl.):27S-32S.
13. Comabella M., Domínguez C., Rio J., Martín-Gallán P., Vilches A., Vilarrasa N., Espejo C., Montalban X. Plasma chitotriosidase activity in multiple sclerosis. Clin. Immunol. 2009, 131:216-222.
14. De Boulle K. Management of complications after implantation of fillers. J. Cosmet. Dermatol. 2004, 3:2-15.
15. de Bree R., Middelweerd M.J., van der Waal I. Severe granulomatous inflammatory response induced by injection of polyacrylamide gel into the facial tissue. Arch. Facial Plast. Surg. 2004, 6:204-206.
16. Dhiman M., Estrada-Franco J.G., Pando J.M., Ramirez-Aguilar F.J., Spratt H., Vazquez-Corzo S., Perez-Molina G., Gallegos-Sandoval R., Moreno R., Garg N.J. Increased myeloperoxidase activity and protein nitration are indicators of inflammation in patients with Chagas' disease. Clin. Vaccine Immunol. 2009, 16:660-666.
17. Duffy D.M. Complications of fillers: overview. Dermatol. Surg. 2005, 31(11 Pt. 2):1626-1633.
18. Edwards P.C., Fantasia J.E. Review of long-term adverse effects associated with the use of chemically-modified animal and nonanimal source hyaluronic acid dermal fillers. Clin. Interv. Aging 2007, 2:509-519.
19. Engelman D.E., Bloom D., Goldberg D.J. Dermal fillers: complications and informed consent. J. Cosmet. Laser Ther. 2005, 7:29-32.
20. Gladstone H.B., Cohen J.L. Adverse effects when injecting facial fillers. Semin. Cutan. Med. Surg. 2007, 26:34-39.
21. Glasgold M., Lam S.M., Glasgold R. Autologous fat grafting for cosmetic enhancement of the perioral region. Facial Plast. Surg. Clin. North Am. 2007, 15:461-470.
22. Golberg D.J. Calcium hydroxylapatite. Fillers in Cosmetic Dermatology 2006, Informa UK Ltd., Abingdon, England, pp. 81-109.
23. Hansson M., Olsson I., Nauseef W.M. Biosynthesis, processing, and sorting of human myeloperoxidase. Arch. Biochem. Biophys. 2006, 445:214-224.
24. Hollak C.E., van Weely S., van Oers M.H., Aerts J.M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 1994, 93:1288-1292.
25. Johansen J.S. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan. Med. Bull. 2006, 53:172-209.
26. Kaneda H., Taguchi J., Ogasawara K., Aizawa T., Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002, 162:221-225.
27. Klebanoff S.J. Myeloperoxidase: friend and foe. J. Leukoc. Biol. 2005, 77:598-625.
28. Krzystek-Korpacka M., Neubauer K., Berdowska I., Boehm D., Zielinski B., Petryszyn P., Terlecki G., Paradowski L., Gamian A. Enhanced formation of advanced oxidation protein products in IBD. Inflamm. Bowel Dis. 2008, 14:794-802.
29. Kzhyshkowska J., Gratchev A., Goerdt S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark. Insights 2007, 2:128-146.
30. Lau D., Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol. Ther. 2006, 111:16-26.
31. Lemperle G., Gauthier-Hazan N., Wolters M., Eisemann-Klein M., Zimmermann U., Duffy D.M. Foreign body granulomas after all injectable dermal fillers: Part 1. Possible causes. Plast. Reconstr. Surg. 2009, 123:1842-1863.
32. Lowe N.J., Maxwell C.A., Patnaik R. Adverse reactions to dermal fillers: review. Dermatol. Surg. 2005, 31:1616-1625.
33. Margaritopoulos G.A., Antoniou K.M., Karagiannis K., Samara K.D., Lasithiotaki I., Vassalou E., Lymbouridou R., Koutala H., Siafakas N.M. Investigation of toll-like receptors in the pathogenesis of fibrotic and granulomatous disorders: a bronchoalveolar lavage study. Fibrog. Tissue Repair 2010, 3:20.
34. Martín-Gallán P., Carrascosa A., Gussinyé M., Domínguez C. Changes in oxidant-antioxidant status in young diabetic patients from clinical onset onwards. J. Cell. Mol. Med. 2007, 11:1352-1366.
35. Matarasso S.L. Injectable collagens: lost but not forgotten-a review of products, indications, and injection techniques. Plast. Reconstr. Surg. 2007, 120(Suppl.):17-26.
36. Miro-Mur F., Hindié M., Kandhaya-Pillai R., Tobajas V., Schwartz S., Alijotas-Reig J. Medical-grade silicone induces release of proinflammatory cytokines in peripheral blood mononuclear cells without activating T cells. J. Biomed. Mater. Res. B: Appl. Biomater. 2009, 90(2):510-520.
37. Ogden A., Griffiths T.W. A review of minimally invasive cosmetic procedures. Br. J. Dermatol. 2008, 159:1036-1050.
38. Piacquadio D., Smith S., Anderson R. A comparison of commercially available polymethylmethacrylate-based soft tissue fillers. Dermatol. Surg. 2008, 34(Suppl. 1):S48-S52.
39. Rathcke C.N., Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm. Res. 2006, 55:221-227.
40. Rathcke C.N., Vestergaard H. YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc. Diabetol. 2009, 8:61.
41. Rossner M., Rossner F., Bachmann F., Wiest L., Rzany B. Risk of severe adverse reactions to an injectable filler based on a fixed combination of hydroxyethylmethacrylate and ethylmethacrylate with hyaluronic acid. Dermatol. Surg. 2009, 35:367-374.
42. Sánchez-Carpintero I., Candelas D., Ruíz-Rodríguez R. Dermal fillers: types, indications, and complications. Actas Dermosifiliogr. 2010, 101:381-393.
43. Shimasaki H. Assay of fluorescent lipid peroxidation products. Methods Enzymol. 1994, 233:338-346.
44. Sugiyama S., Okada Y., Sukhova G.K., Virmani R., Heinecke J.W., Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am. J. Pathol. 2001, 158:879-891.
45. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
46. van Eijk M., van Roomen C.P., Renkema G.H., Bussink A.P., Andrews L., Blommaart E.F., Sugar A., Verhoeven A.J., Boot R.G., Aerts J.M. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int. Immunol. 2005, 17:1505-1512.
47. Vleggaar D., Bauer U. Facial enhancement and the European experience with Sculptra (poly-l-lactic acid). J. Drugs Dermatol. 2004, 3:542-547.
48. Witko-Sarsat V., Friedlander M., Capeillère-Blandin C., Nguyen-Khoa T., Nguyen A.T., Zingraff J., Jungers P., Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996, 49:1304-1313.